Multiple Myeloma Hub
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Oct 2, 2022
Roman Hájek, from the University of Ostrava, discusses the benefits of isatuximab-based combinations in treating relapsed multiple myeloma patients refractory to lenalidomide-based therapy. The focus is on the efficacy of isatuximab with carfilzomib and dexamethasone, highlighting the role of immunomodulatory agents in improving outcomes.
03:03
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Isatuximab in combination with carfilzomib and dexamethasone is highly beneficial for multiple myeloma patients refractory to lenalidomide-based therapy.
- Immunomodulatory agents like Isatuximab offer significant advancements in multiple myeloma treatment efficacy, particularly for patients refractory to lenalidomide-based regimens.
Deep dives
Role of Isatuximab in Combination Therapy
Isatuximab, an anti-CD38 monoclonal antibody, has shown significant benefits in combination therapy for multiple myeloma patients. In particular, when combined with carfilzomib and dexamethasone, it demonstrated a substantial advantage over other treatments. The efficacy of this combination was especially highlighted in patients who were refractory to lenalidomide-based therapy, offering a robust and potent treatment option.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
